VKH
STML

Virtu KCG Holdings’s Stemline Therapeutics, Inc. STML Stock Holding History

Virtu KCG Holdings’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-12,012
Closed -$56K – 3489
2016
Q1 		$56K Sell
12,012
-7,309
-38% -$35.7K ﹤0.01% 2442
2015
Q4 		$122K Buy
+19,321
New +$157K ﹤0.01% 2928

Other funds holding STML

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Virtu KCG Holdings's STML Position: Q2 2016 in Review

Virtu KCG Holdings sold out of Stemline Therapeutics, Inc. (STML) in Q2 2016, closing a stake of 12,012 shares — an estimated $56K sold.

Virtu KCG Holdings first reported a position in STML in Q4 2015 and held it in 2 quarters. The position peaked at $122K in Q4 2015. 61 funds tracked by Wall St. Rank hold STML as of Q2 2016.

  • Virtu KCG Holdings reported no remaining Stemline Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • Virtu KCG Holdings sold 12,012 Stemline Therapeutics, Inc. shares in Q2 2016, an estimated $56K.
  • Virtu KCG Holdings first reported a position in Stemline Therapeutics, Inc. in Q4 2015 and held it in 2 quarters.
  • Virtu KCG Holdings's Stemline Therapeutics, Inc. position peaked at $122K in Q4 2015.
  • 61 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2016.

Based on Virtu KCG Holdings's 13F filing for Q2 2016, filed 12 Aug 2016.